目的 分析惠州地区高尿酸血症患病率,探讨血清雌二醇水平与高尿酸症之间的相关性。方法 选择惠州市第一人民医院500名体检人员为研究对象,检测血清中尿酸浓度,女性同时检测雌二醇。结果 惠州地区高尿酸血症总患病率为23.2%(116/500),男性及女性分别为27.91%(72/258)和18.18%(44/242)(χ²＝6.628,P=0.010),不同性别血清尿酸浓度差异显著(Z=-15.961,P<0.001)。各年龄段男性血清尿酸水平(χ²=6.432,P=0.169)及患病率(χ²＝3.989,P=0.408)均相近。50岁以上女性患病率与男性无差异(χ²=0.088,P=0.766),20～49岁女性血清尿酸水平(Z=-3.856,P<0.001)及患病率(χ²=9.532,P=0.002)均低于50岁以上女性。20～49岁女性雌二醇高于50岁以上女性(Z＝-6.171,P<0.001),尿酸与雌二醇具有负相关性,r=-0.464。结论 除50岁以上女性外,惠州地区健康人群高尿酸血症患病率与国内多数地区人群相近,女性50岁进入绝经期后高尿酸血症患病率的快速上升与体内雌激素下降呈负相关。

Objective To analyze the prevalence rate of hyperuricemia (HUA) in Huizhou and investigate the relationship between HUA and estradiol(E2). Methods 500 health people from Huizhou first hospital were enrolled. Uric acid and E2 in female was detected. Results The overall prevalence rate of HUA was 23.2%(116/500). The prevalence rate of male and female were 27.91% (72/258)and 18.18%(44/242), respectively(χ²＝6.628,P=0.010). There was no significantly difference between male and female in the level of uric acid(Z=-15.961,P<0.001) The levels ofuricacid in serum(χ²=6.432,P=0.169)and the prevalence rate (χ²＝1.1,P>0.05)were closed to each age bracket in male group. The prevalence rate of male over 50 years old was closed to female(χ²=0.0144,P>0.05).In 20 to 49 years old female group, prevalence rate was lower(χ²=6.084,P<0.025) and uric acid in serum(χ²=17.599,P<0.001)was lower than that of the group over 50 years old. The levels of E2 of female under 50 years old was higher than that above 50 years old(χ²＝41.292,P<0.001).There was negative correlation between uric acid and E2, and the correlation coefficient was -0.464. Conclusion The prevalence rate of HUA in Huizhou is close to most area in China except female over 50 years old. After menopause, the rapid rise of prevalence rate of HUA in female is associated with the descending of E2.

目的 探讨中药吴茱萸治疗术后早期炎性肠梗阻的临床疗效,并探讨其应用价值。方法 将50例术后早期炎性肠梗阻患者随机分为治疗组(吴茱萸封包+常规西药治疗)和对照组(常规西药治疗),观察比较腹胀、腹痛、便秘、呕吐等临床表现、腹平片结果;对比分析2组患者腹胀缓解时间、肠鸣音恢复时间、排气排便时间、胃液引流量。结果 ①治疗组治愈率80.8%,高于对照组41.7%,有差异(P＜0.01);②治疗组腹胀缓解、肠鸣音恢复、肛门排气排便时间及24 h胃液引流量均较对照组缩短,差异有统计学意义(P＜0.05)。结论 吴茱萸封包穴位外敷能显著提高术后早期炎性肠梗阻临床疗效。

Objective To explore the clinical curative effect of Wuzhuyu in treatment of early inflammatory bowel obstruction and its application value. Methods 50 cases of early inflammatory bowel obstruction were randomly divided into the treatment group (Wuzhuyu packet+conventional western medicine treatment) and the control group (routine western medicine treatment), to observe the results of abdominal distention, abdominal pain, constipation, vomiting. The time of abdominal distension of the two groups, the recovery time of the bowel sound, the time of exhaust defecation and the drainage of gastric juice were compared and analyzed. Results ① The cure rate of treatment group 80.8% was higher than the control group of 41.7%, and the difference was statistical significant (P<0.01);② the time of abdominal distention of the treatment group, the recovery of the intestinal singing tone, the time of exhaust defecation and the drainage of the gastric juice were shortened than that of the control group, and the difference was statistical significant (P< 0.05). Conclusion The clinical effect of the treatment of early postoperative inflammatory bowel obstruction may be significantly improved by Wuzhuyu closure.

目的 探讨品管圈活动在提高神经外科卧床患者便秘预防措施落实率中的的应用效果。方法 成立品管圈,确定以“提高神经外科卧床患者便秘预防措施落实率”为主题,进行现状调查,设定目标,进行要因分析,制定并实施措施,比较品管圈活动前后护士落实便秘预防措施情况。结果 实施品管圈活动后,神经外科卧床患者便秘预防措施落实率从活动前的41.59%上升至活动后85.6%,差异有统计学意义(P＜0.05)。结论 品管圈活动可以有效提高神经外科卧床患者便秘预防措施落实率,降低便秘的发生率,减轻患者痛苦,改善患者生活质量。

目的 探讨入院准备中心制度在我院乳腺外科住院预约统筹管理的实践情况。方法 2017年1月—12月广州市第一人民医院入院准备中心对乳腺外科30张床位实施病床集中预约管理,依据患者病情进行预约,合理安排患者入院。结果 2017年1至12月我院乳腺外科共预约入院1225人/次,成功办理预入院1096人/次,约占乳腺外科总入院人数的77.85%。预入院进行手术患者415人/次,其中3日内手术患者为285人/次,预入院三日内手术率为68.67%。结论 预入院制度对乳腺外科病床进行集中预约管理能有效保证床位充分使用,为患者提供方便、有效的医疗服务,值得基层医院推广。

目的 探讨6野切线射野方式调强放疗(6F-IMRT)用于左侧乳腺癌根治术后放疗的临床价值。方法 纳入我院70例左侧乳腺癌根治术患者为研究对象,进行模拟CT增强扫描,三维重建后勾画大体靶区,分别对每个患者靶区设计4F-IMRT、5F-IMRT、6F-IMRT三种治疗计划,规定计划靶区(PTV)达到95%的处方剂量前提下,分析三种治疗计划PTV所受照射的平均剂量、最大剂量、最小剂量,95%、100%等剂量线包绕的靶区体积(V₉₅、V₁₀₀),适形度指数(CI)及剂量不均匀指数(HI),并比较三种计划下心脏、双肺、右乳受照射剂量。结果 各治疗计划靶区最大剂量、最小剂量、平均剂量比较无统计学意义(P＞0.05)。6F-IMRT的V₉₅、V₁₀₀均高于4F-IMRT、5F-IMRT,差异有统计意义(P＜0.05)。4F-IMRT、5F-IMRT、6F-IMRT的CI呈递增趋势,HI呈递减趋势,各组间比较差异有统计学意义(P＜0.05)。三种放疗计划中心脏的平均剂量、V₃₀,双肺的平均剂量、V₂₀、右乳平均剂量比较无显著差异(P＞0.05)。三种放疗计划中,4F-IMRT右乳V₁₀显著低于5F-IMRT、6F-IMRT,差异有统计学意义(P＜0.05),但均在最大耐受剂量范围内。结论 与4F-IMRT、5F-IMRT相比,6F-IMRT用于左侧乳腺癌根治术后放疗有明显剂量学优势,可提高靶区照射剂量,靶区适形程度及剂量均匀性均较好,而且并不会增加周围正常器官照射剂量。

目的 研究宫腔镜治疗子宫粘连性所致不孕症的临床疗效,为临床相关治疗提供参考。方法 选取我院于2016年11月—2017年11月收治的180例子宫粘连性所致不孕症患者作为观察对象,按照随机数表法平均分成两组。其中观察组90例采用宫腔镜治疗,对照组90例采用传统输卵管通液治疗。对比两组患者治疗前后性激素水平、临床指标及妊娠结局变化。结果 两组间相比,治疗前后 LH、FSH、E2、P等性激素水平无变化,且治疗后观察组与对照组相比,差异均无统计学意义(P>0. 05);两组间相比,治疗后观察组患者的术中出血量、手术时间、住院天数均少于对照组,差异有统计学意义(P<0. 05);两组间相比,治疗后观察组患者的足月分娩率高于对照组,早产率低于对照组,差异有统计学意义(P<0. 05)。结论 宫腔镜治疗子宫粘连性所致不孕症,与传统输卵管通液治疗相比,对性激素水平无影响,但可显著降低患者住院时间及术中出血量,有效提高足月分娩率,值得在临床上推广。

目的 分析河源地区医疗机构临床用血合理性现状,提高临床合理输血水平。方法 选择本地区临床用血量前三位的3家综合性医院,随机抽取其2017年住院患者1 012例输血病例,判断每次输血合理性并对不合理输血原因进行分析。结果 1 012份输血病例中合理输血病例718例,合理性输血比例为70.94%。不同血制品和临床科室间用血合理性比例差异具有统计学意义(χ²=6.734、6.119,P=0.000、0.000)。红细胞输注不合理原因主要为指征过宽和无指征输血,血浆、血小板、冷沉淀输注不合理原因主要为无指征输血。结论 加强医疗机构临床用血管理,真正做到科学用血、合理用血,节约用血。

目的 探讨重组人表皮生长因子滴眼液联合玻璃酸钠治疗白内障术后干眼症的随机对照情况。方法 选取2017年度在本院实施白内障术后发生干眼症患者120例,采取随机分组方法分成观察组、对照组各60例,观察组给予重组人表皮生长因子滴眼液联合玻璃酸钠治疗,对照组给予玻璃酸钠滴眼液治疗,比较两组患者的临床疗效情况。结果 观察组有效率90%高于对照组73.33%,有差异;两组患者治疗前FL、BUT、SIT比较均无差异,P>0.05;治疗后,两组FL、BUT、SIT比较有差异,P<0.05; 两组患者治疗前视力评价比较均无差异,P>0.05;治疗后,两组视力评价比较有差异,P<0.05。结论 给予白内障术后干眼症患者采取重组人表皮生长因子滴眼液联合玻璃酸钠治疗,可提高临床疗效,对于改善相关临床体征、视力指标均具有重要临床价值。

目的 研究对比胃癌患者术前胃镜活检病理与外科术后病理的异同并进行观察。方法 选取我院消化科于2016年7月—2017年12月收治的64例胃癌患者作为此次研究对象,术前均展开胃镜活检,术后展开外科病理检查,判断两种诊断方法的异同。结果 胃癌确诊率对比,术前胃镜活检后确诊胃癌患者占比85.9%(55/64),疑似胃癌患者占比10.9%(7/64),排除胃癌患者占比3.1%(2/64),术前胃镜活检确诊率85.9%,低于术后病理诊断95.3%,组间比较差异无统计学意义(P>0.05);胃镜活检病理结果对比,术前胃镜检查黏液腺癌占比35.9%,乳头状腺癌占比51.6%,均高于术后病理检查的25.0%、28.1%,组间比较差异具有统计学意义(P＜0.05);胃镜活检分化程度结果对比,胃镜病理与术后病理检查结果对比有明显差异,具有统计学意义(P＜0.05)。结论 对胃癌进行诊断时,尽管术前胃镜活检病理检查与外科术后病理检查结果存在差异,但术前胃镜活检对胃癌确诊率较为理想,可作为术前诊断参考,外科术后病理检查对全面评估胃癌病情具有较高应用价值,值得在临床中应用。

目的 对比分析甲氨蝶呤(methorexate,MTX)联合超声监视下清宫与甲氨蝶呤、子宫动脉栓塞术(uterine artery embolization,UAE)联合清宫治疗停经7周内Ⅱ-Ⅲ型剖宫产瘢痕妊娠(ceasarean scarpregnancy,CSP)的效果。方法 回顾性分析我院自2016年1月—2017年12月收治的停经7周内Ⅱ-Ⅲ型CSP患者的临床资料,按随机、平衡、对照原则分别筛选69例MTX+清宫治疗患者作为A组,68例MTX+UAE+清宫治疗患者作为B组,对比两组治疗成功率、一般治疗情况及术后并发症发生率,并统计两组月经周期恢复时间、血β-hCG恢复至正常时间、疤痕妊娠病灶消失时间。结果 两组术后恢复良好,术中、术后均未发生不可控制宫腔出血现象,胎囊组织均全部清出,A组术中出血量、子宫切除发生率、发热、术后盆腹腔疼痛及肝功能损伤发生率均低于B组,术后第1天血β-hCG下降超过50%及治疗成功率、住院时间均高于B组,且该组月经周期恢复时间、血β-hCG恢复至正常时间、疤痕妊娠病灶消失时间亦较B组短(P﹤0.05)。结论 于停经7周内Ⅱ-Ⅲ型CSP患者而言,行MTX+清宫治疗或可在不增加出血风险基础上避免UAE相关并发症及副反应。

Objective To comparatively analyze the effects of methotrexate (MTX) combined with uterine curettage under ultrasonic monitoring and MTX, uterine artery embolization (UAE) combined with uterine curettage in the treatment of cesarean scar pregnancy (CSP) within 7 weeks of menopause. Methods The clinical data of patients with type Ⅱ-Ⅲ CSP within 7 weeks of menopause who were admitted to the hospital from January 2016 to December 2017 were analyzed retrospectively. Another 69 cases treated with MTX combined with uterine curettage were selected as group A and 68 cases treated with MTX+UAE+uterine curettage were selected as group B. The success rate of treatment, general situation of treatment and the incidence of adverse reactions were compared between the two groups. The time of menstrual recovery, the recovery time of blood β-hCG and the disappearance time of scar pregnancy lesions were statistically analyzed. Results The two groups recovered well after operation, and there was no uncontrollable uterine bleeding. All fetal sac tissues were cleared. The intraoperative blood loss, hysterectomy rate, incidence rates of fever, postoperative abdominopelvic pain and liver function injury in group A were less/lower than those in group B, The rate of blood β-hCG decreasing more than 50% on the 1st day after operation, the success rate of treatment and hospitalization time of groups A were higher/longer than those of group B, while the time of menstrual recovery, recovery time of blood β-hCG and the disappearance time of scar pregnancy lesions was shorter than that of group B(P<0.05). Conclusion MTX combined with uterine curettage may avoid complications and side effects of UAE in patients with type Ⅱ-Ⅲ CSP within 7 weeks of menopause, without increasing the risk of bleeding.